Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Clinical trial NCT07701889 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07701889
- Sponsor
- Roswell Park Cancer Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-01
- Primary completion
- 2028-10-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.